– USA, MA – Tessera Therapeutics, the biotechnology company pioneering GENE WRITING technology, today announced the appointment of Derica Rice to its Board of Directors, bringing his vast pharmaceutical and healthcare leadership experience to the board.
“Derica is an exceptional leader and champion for innovative therapies with the potential to transform human health. Derica’s intimate knowledge of the commercial and payor landscape will be vital as Tessera brings GENE WRITING products to patients and ensures that they are both effective and accessible to those who need them,” said co-founder and board chair, Dr. Geoffrey von Maltzahn.
About Derica Rice
Derica Rice is an accomplished executive with decades of experience managing and overseeing a wide range of financial and accounting matters, including financial oversight, risk management, and the alignment of financial and strategic initiatives. He led the pharmacy benefits business of CVS Health as Operational, EVP, and President of CVS Caremark. Before his time at CVS Health, Mr. Rice spent 27 years guiding Eli Lilly’s financial and strategy functions, eventually serving as EVP of Global Services and as CFO.
In addition to Mr. Rice’s tenure in the pharmaceutical industry, he is a board member of Disney, The Carlyle Group, and Target, and serves on the Audit Committee for BMS.
Mr. Rice earned his MBA from Indiana University and graduated with a B.S. in Electrical and Electronics Engineering at Kettering University.
About Tessera Therapeutics
Tessera Therapeutics is pioneering GENE WRITING technology, which consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source. The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo. Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.
For more information: https://www.tesseratherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
